Sentences with phrase «tumor cell vaccine»

Researchers used IL - 15 to develop a whole tumor cell vaccine to target breast (TS / A) and prostate (TRAMP - C2) cancer cells in animal models; results showed that tumor cells stopped growing after the vaccine was introduced and that beneficial effects were enhanced further when IL - 15Rα was co-produced by the vaccine cells.

Not exact matches

Today his company is developing a new cancer vaccine technology that teaches immune cells how to recognize and remove tumor cells.

His work indicates that this cell surface marker could serve as a target for a novel brain cancer vaccine or T - cell therapies engineered to recognize and kill tumors carrying that neoantigen.

Or consider a vaccine that, when injected directly into a tumor, would not only destroy the malignant cells but also stimulate the body's immune system to go after similar tumor cells.

As researchers learn more about genetic profile of various cancers, other work is charging ahead to deliver personalized vaccines targeted to a patient's own tumor cells

Like all cancer vaccines, it's been a challenge to get dendritic cell immunotherapy to destroy tumors in people.

Most cancer vaccines developed to date have been designed to recognize and attack a specific known molecule — such as a cell - surface receptor — that is likely to be found on cancerous cells in any patient with that type of tumor.

The personalized vaccine is made from patients» own immune cells, which are exposed in the laboratory to the contents of the patients» tumor cells, and then injected into the patients to initiate a wider immune response.

The vaccine harnesses the natural process of T - cell immunity to tumors, but enhances it to help overcome tumors» formidable defenses.

Moderna is also doing animal safety tests of a personalized cancer vaccine that would code for immune - activating proteins unique to a person's cancer cells, based on genetic sequencing of their tumor.

CTL119 manufacturing begins with a patient's own T cells, some of which are removed and then reprogrammed in Penn's Clinical Cell and Vaccine Production Facility with a gene transfer technique designed to teach the T cells to target and kill tumor cells.

To make the vaccine, cancer cells are harvested from a tumor after surgery and stripped of their proteins; then those proteins are cultured with dendritic cells, a subclass of white blood cells, drawn from the patient's blood.

Dendritic cells are too large to pass through the blood - brain barrier, which is one reason they have to be cultured with brain tumor cells outside the body, then injected back into the patient's skin as a vaccine.

«Additionally, this provides evidence needed to begin investigating a vaccine in human cancer clinical trials to determine whether genetically modified tumor cells producing IL - 15 and IL - 15Rα may induce anti-cancer responses.»

Cincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune system, could initiate the immune response to fight cancer.

Instead, the vaccines use killed autologous tumor cells from the patient to activate the immune system.

To make the vaccine, researchers took a sample of a patient's tumors, which in this trial were made up of B cells (white blood cells that help the body battle disease and infection).

What's more, IL - 33 and the DNA vaccine augmented immunological responses in both CD4 helper T cells and CD8 killer T cells, with a large proportion of CD8 killer T cells demonstrating a further improvement in the ability of DNA vaccines to drive the immune system to kill tumor cells in animals.

«We found that the NFkB - Pim1 - Eomes axis, an important molecular mechanism that operates in memory T cells, could be enhanced with molecular or genetic strategies to help current vaccines or tumor therapies be more effective.

When injected into mice that were then given a subsequent injection of lymphoma cells, the 3D vaccine generated a potent immune response and delayed tumor growth.

While this approach has had some clinical success, in most cases, the immune response resulting from dendritic cell vaccines is short - lived and not robust enough to keep tumors at bay over the long run.

Antibodies stimulate the recruitment of additional immune cells that help to activate T cells; the vaccine stimulates proliferation of T cells that can attack the tumor; IL - 2 helps the T cell population to expand quickly; and the anti-PD1 molecule helps T cells stay active longer.

The resulting treatment consists of four parts: an antibody targeted to the tumor; a vaccine targeted to the tumor; IL - 2; and a molecule that blocks PD1, a receptor found on T cells.

The vaccine is unique to the individual participant and is engineered to trigger an immune system response to kill tumor cells that may remain following surgery.

The therapeutic cancer vaccine employs nanodiscs loaded with tumor neoantigens, which are unique mutations found in tumor cells.

A vaccine that targets cancer stem cells dramatically limits tumor growth in mice, researchers reported in April.

The researchers found that the personal vaccine induced a focused T cell response against several tumor neoantigens, beyond what is normally seen in response to existing immunotherapies.

Most importantly, many of the T cells were able to recognize the tumor cells directly, demonstrating that the vaccine had triggered a tumor - specific immune response that could target the patient's tumor.

A personal cancer treatment vaccine that targets distinctive «neoantigens» on tumor cells has been shown to stimulate a potent, safe, and highly specific immune anti-tumor response in melanoma patients, report scientists from Dana - Farber Cancer Institute and the Broad Institute of MIT and Harvard.

To supply tumor cells for the vaccine, such patients would still have to undergo surgical removal of their tumors.

Scientists will probably have to find a way to make larger supplies of vaccine with a limited supply of tumor cells, Tanyi said.

The symposium features presentations by Philippa Marrack and John Kappler talking on the T cell repertoire; William Paul on interleukin 4 as a prototypic immunoregulatory cytokine; Timothy Springer on lymphocyte trafficking; Pamela Bjorkman on structural studies of MHC and MHC - related proteins, and Jack Strominger on peptide presentation by class I and II MHC proteins; Thierry Boon on genes coding for tumor rejection antigens, including the first tumor antigen, MAGE - 1; and Philip Greenberg on the modification of T cells for adoptive therapy by retroviral - mediated gene insertion Since then, the symposia series has attracted leading immunologists in the cancer vaccine and antibody fields, providing them with a comprehensive view of the promises and challenges in the development of cancer immunotherapies.

As demonstrated by the breadth of clinical trial involvement shown above, CCIR members are testing the utility of immune checkpoint blockade in lymphoma (shown by Dr. Allison to be effective against melanoma), genetic engineering in cell therapy (e.g., CD19, CXCR2, TGF - β DNR), and TLR agonists or IL - 2 in vaccine formulations as well as some novel combination therapies, such as the infusion of tumor - reactive lymphocytes from HLA - matched donors who were vaccinated with a lymphoma idiotype.

We need a new type of vaccine that uses select components of a microbe or tumor cell or other cause of disease, and administers these with other defined substances, such as adjuvants, that directly exploit immunology.»

Drew Pardoll, Glenn Dranoff, Elizabeth Jaffee, Hyam Levitsky, and colleagues conduct preclinical studies showing that a vaccine composed of tumor cells irradiated and genetically modified to produce immune system growth factor GM - CSF (granulocyte - macrophage colony - stimulating factor)-- which would become known as the therapeutic cancer vaccine GVAX — could induce potent, specific, and long - lasting anti-tumor immunity in multiple mouse tumor models.

'» In all patients who were vaccinated, his team found tumor - targeting T cells, and he noted that in addition to augmenting pre-existing T cell responses, the vaccine also stimulated new T cell responses against tumors.

Cancer vaccines are designed to stimulate an immune response against tumor - specific or tumor - associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.

Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell - based hyperthermic tumor vaccine.

In addition, it was increasingly recognized that oncolytic viruses not only were able to directly lyse cancer cells, but they also «freed «tumor specific neoantigens, indirectly acting as a cancer vaccine.

Vaccines that aim to expand tumor - specific CD8 (+) T cells have yielded disappointing results in cancer patients although they showed efficacy in transplantable tumor mouse models.

A new UC San Francisco study has shown that a cancer - killing («oncolytic») virus currently in clinical trials may function as a cancer vaccine — in addition to killing some cancer cells directly, the virus alerts the immune system to the presence of a tumor, triggering a powerful, widespread immune response that kills cancer cells far outside the virus - infected region.

Therapeutic vaccines are designed to elicit an immune response against tumor - specific or tumor - associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.

Tags: aspirin, Bezos, bioengineering, Breast Cancer, Cameron Turtle, Cancer etiology - prevention - outcomes, CAR t - cell, Clinical Research, Colorectal Cancer, genome, hiv, hiv vaccine, hiv vaccine trials network, Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell carcinoma, metastasis, Molecular basis of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viral vaccine, hiv vaccine trials network, Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell carcinoma, metastasis, Molecular basis of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viral vaccine trials network, Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell carcinoma, metastasis, Molecular basis of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viral Vaccine and Infectious Disease, Vaccine development - Viral Vaccine development - Viral cancers

His lab has extensive experience evaluating and modulating T cell responses to tumors and viruses, including introducing genes into T cells to impart specificity and modulate function, designing strategies to overcome tolerance and enhance in vivo activity, and developing mouse models that more accurately model human immune responses to candidate vaccines.

Similarly, MVA - p53 vaccine is targeted at the p53 protein, a tumor suppressor that contols how cells divide and replicate.

The lab also found that apoptotic tumor cells serve as potent instigators of the T cell immune response and has worked on developing cancer vaccines to mimic PND tumor immunity.

Therapeutic cancer vaccines are designed to elicit an immune response against tumor - specific or tumor - associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.

This hematoxylin and eosin stained slide of a surgically removed (resected) primary pancreatic tumor shows a cluster of immune cells (lymphoid aggregate) observed next to a pancreatic tumor lesion in a patient treated with a GM - CSF vaccine 2 weeks before surgical removal of the primary tumor.

2000 Johns Hopkins Cancer Center researchers develop a pancreatic cancer vaccine and prove it activates immune cells against pancreatic tumor cells.

Sandoval F, Terme M, Nizard M, Badoual C, Bureau MF, Freyburger L, Clement O, Marcheteau E, Gey A, Fraisse G, Bouguin C, Merillon N, Dransart E, Tran T, Quintin - Colonna F, Autret G, Thiebaud M, Suleman F, Riffault S, Wu TC et al. (2013) Mucosal Imprinting of Vaccine - Induced CD8 + T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors.